A Study to Investigate How Safe and Well Tolerated RV568 is in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status:
Completed
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
RV568 is being developed as a possible treatment of diseases such as smoking related lung
disease (also known as Chronic Obstructive Pulmonary Disease - COPD) and asthma.
The main purpose of this study is to examine the safety of RV568 in COPD patients. Two dose
strengths of RV568 and a placebo will be tested in this study, which will be given by
inhaling a liquid suspension from a nebuliser once a day for 2 weeks.